Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography Angiography
NCT ID: NCT06543641
Last Updated: 2024-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2023-01-16
2024-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Can patency of long coronary artery stents be assessed with third generation CCTA?
* What are the factors affecting the assessability?
* What is the radiation exposure of third generation CCTA?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serial OCT Evaluation of Tissue Coverage in Patients Submitted to Inspiron Drug Eluting Stent Implantation
NCT03269461
StEnt Coverage and Neointimal Tissue Characterization After eXtra Long evErolimus - Eluting Stent imPlantation
NCT03401216
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
NCT05544864
The 3D Stent Study
NCT06898021
Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents
NCT01056744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patient selection A registry that included chronic total occlusion (CTO) patients with stable coronary artery disease treated for CTO with percutaneous coronary angioplasty (CTO PCI) in Helsinki University Central Hospital starting from 2014 was used for this study. The study population included consecutive, prospectively recruited patients from 2014 to 2019. All patients meeting the study criteria were included in the study.
Definition Segments 5 mm proximal and 5 mm distal to the stent were considered as part of the stent for in-stent restenosis (ISR) evaluation, as proposed by the Academic Research Consortium and were included in CCTA performance analyses. Long CTO stents consisted of one or more coronary artery stents with possible combination of different stent types. The combined stent length was reported without possible overlap for multiple stents. The diameter of the largest stent or post-dilation balloon was reported. Based on previous CT studies and guidelines radiological ISR in CCTA was defined as luminal narrowing of ≥ 50% in the long CTO stent. CCTA result was considered negative if ISR was ruled out and positive if ISR was detected or if the result was inconclusive. Therefore, two groups defined by the CCTA result were formed. In patient-based analyses patients with two long CTO stents of which at least one was a CCTA positive stent were considered as CCTA positive. In native coronary arteries less than 25% was considered minimal, 25-49% mild, 50-69% moderate and 70-99% severe stenosis and 100% as an occlusion. Assessment of stenosis was based on direct visualisation. The study's experienced cardiac radiologist with over 15 years of experience was blinded for symptomatic data, stent type and stent quantity. The target vessel of implanted coronary artery stents was provided.
All patients underwent third-generation dual-source CCTA. In CCTA a non-contrast calcium score using standard 120 kilovolt (kV) acquisition and 3 mm slice thickness was obtained. Stented segments were manually subtracted from the score. Second, third-generation dual-source CCTA (Somatom Force, Siemens) was performed. Prospective ECG-triggering was applied regular heart rate \< 70/min and/or in the case of previous stent implantation of right coronary artery (RCA) to avoid motion artefacts and FLASH- mode if the heart rate was regular and \< 60/min. If the presenting heart rate was \> 70/min, metoprolol 5-15 mg was administered intravenously. For patients with higher heart rates (\> 70/min) prospective ECG-gating and widening of the acquisition window (padding) were used. Sublingual nitroglycerin was administered before scanning. A tube voltage of 100 kV, rotation time of 0.25 s, temporal resolution of 66 ms, collimation of 2 x 192 x 0.6 mm and pitch of 3.2 were used. Approximately 50 ml of contrast medium containing 350 mg/ml of iodine (Omnipaque 350, GE Healthcare) was injected intravenously at a flow rate of 5-5.7 ml/s, followed by a 47 ml saline solute. Axial images were reconstructed with 0.6 mm slice and evaluated using multiplanar reformation. Bv40 kernel, Advanced Modeled Iterative Reconstruction 3 (ADMIRE 3) and Iterative metal artefact reduction (iMAR) were utilised.
Clinical information and CCTA results were assessed by the interventional cardiologists and the following patients were offered invasive coronary angiography (ICA):
1. Patients with a positive result in a long CTO stent
2. Patients with a positive result in a non-CTO stent
3. Patients with ≥ 50% stenosis or an inconclusive finding in any native coronary artery in patients with anginal symptoms.
Physiological evaluation (fractional flow reserve) and intravascular imaging (intravascular ultrasound, optical coherence tomography) were performed in ICA by the decision of the interventional cardiologist. Any incidental findings were evaluated separately.
Radiation exposures of CCTA and ICA were reported in dose length product (DLP, milligray\*cm) and dose area product (DAP, gray\*cm2), respectively. DLP was converted to an effective dose (mSv) with a conversion factor of k = 0.014 and DAP with a conversion factor of k = 0.29. The effective doses were compare between patients who received both examinations.
Patients' symptoms were evaluated with the validated Seattle Angina Questionnaire 7 (SAQ7) via a single phone interview. Dyspnea was considered as an anginal symptom. All patients with SAQ7 Anginal Frequency score 100 were considered asymptomatic.
At the CTO PCI, optimal medical therapy was prescribed to all patients.
Stent- and patient-related characteristics examined in the study:
Age (years), body mass index (kg/m2), sex, smoking history, medical conditions at CTO PCI (diabetes, insulin required diabetes, heart failure, peripheral artery disease, dyslipidemia, hypertension, pulmonary disease, chronic kidney disease, atrial fibrillation, cardiac pacemaker, prior myocardial infarction, prior stroke, prior PCI, prior CABG), double-CTO (two treated CTO:s in one procedure), coronary artery dominance (RCA, left circumflex coronary artery (LCX), balanced)), a non-CTO stent implanted in the CTO PCI procedure, clinical presentation (stable angina pectoris or acute coronary syndrome), CCTA Agatston calcium score, stented vessel (RCA, left anterior descending artery (LAD), LCX), Japanese-CTO score (objective index of CTO procedure difficulty), long CTO stent parameters (number of consecutive stents, total stent length (mm), stent length in lesions stented with a single stent (mm), stent length in lesions stented with multiple stents (mm), stent diameter (mm)), duration of the follow-up since stent implantation (years).
The values are presented as medians and IQRs or n (%), as appropriate. The stent lengths are presented as medians and ranges (minimum-maximum).
Statistical analysis Descriptive statistics were reported with median and interquartile range (IQR) for continuous variables, and with frequency (%) for categorical variables. The demographic variables of the CCTA-positive group were compared to the corresponding variables of the CCTA-negative group. Categorical variables were analysed with Fisher's exact test or Pearson's chi-square test, and continuous or ordinal variables with Mann-Whitney U test. The alpha level was 0.05. CCTA performance in evaluating the patency of CTO stents was analysed with sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) in patients receiving both CCTA and ICA. ICA was the reference standard. All the statistical analyses were performed using SPSS version 28 (IBM).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study population
All patients included in the study.
Coronary computed tomography angiography
All patients received coronary computed tomography angiography.
Invasive coronary angiography
According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coronary computed tomography angiography
All patients received coronary computed tomography angiography.
Invasive coronary angiography
According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Successful CTO PCI with a drug-eluting stent
* Primary procedure minimum of four years prior to study date
* CTO stent length ≥ 38 mm in right coronary artery (RCA) and left anterior descending (LAD) coronary artery
* CTO stent length ≥ 30 mm in left circumflex coronary artery (LCX). The definition is clinical.
* Age at primary procedure ≤ 75 years
* Communication in English, Finnish or Swedish
Exclusion Criteria
* Significantly impaired performance in daily activities
* Significant psychiatric disorder
* Active alcohol or drug abuse
* Memory disorder or other cognitive impairment
* Primary procedure in-stent CTO PCI
* Target vessel revascularisation or CABG after the primary - procedure
* Glomerular filtration rate ≤40 ml/min
* ICA or CCTA less than six months prior to the study date
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lauri Mansikkaniemi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lauri Mansikkaniemi
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Petri Laine, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Central Hospital
Helsinki, Uusimaa, Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M1016TUTLA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.